IsoPlexis (company)

It is a biotech company that produces medicines for the treatment of cancer and other diseases. IsoPlexis has developed a platform for identifying the number of proteins in individual cells. The data obtained are used for the production of medicines.

Initially, the focus of IsoPlexis was aimed at creating applications for cancer immunology, as well as for cell and gene therapy. Now the company is expanding its capabilities by developing solutions for the treatment of infectious diseases, inflammatory conditions and neurological diseases.

IsoPlexis Corporation has been in existence since 2013, the commercial launch took place in 2018. Since then, the platform has been used by 15 leading global pharmaceutical companies such as Kite Pharma and Nektar Therapeutics. Also, almost half of the comprehensive cancer centers in the United States use the company's developments.

In the first quarter of 2021, IsoPlexis' revenue amounted to $3.23 million, which is $1.62 million more than in the same period of 2020. During its existence, IsoPlexis has attracted $205.5 million of investments in 13 rounds of financing. The company estimates its potential market at $12 billion. In addition, IsoPlexis plans to develop the field of diagnostic equipment, then the addressable market will increase by $ 34 billion.